Abstract
Brinzolamide is indicated for the reduction of intraocular pressure (IOP) in eyes with ocular hypertension or open-angle glaucoma. Brinzolamide is an effective inhibitor of carbonic anhydrase and lowers IOP by suppressing formation of aqueous humor in the eye. It is formulated as a 1% ophthalmic suspension, with a recommended dosing frequency of three times daily in USA and twice daily in many other locations, including the EU and Japan. The goals of this article are to summarize the preclinical data pertaining to brinzolamide, to review safety and efficacy data from Phase III and Phase IV clinical trials, and to describe the role of brinzolamide in the management of glaucoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
